Clobazam Use in Epilepsia Partialis Continua – Pilot Study

Overview

The purpose of this study is to evaluate whether clobazam, brand name Onf®, is more effective as an adjunctive or monotherapy in terminating Epilepsia Partialis Continua (EPC) than either lorazepam and/or clonazepam.

Full Title of Study: “A Phase III, Randomized, Open Label, Single Center, Study on the Effects of Treatment of Epilepsia Partialis Continua With Clobazam Compared to Treatment With or in Addition to Lorazepam and/or Clonazepam”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Factorial Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2017

Detailed Description

First approved in the United States in 2011 for use in treating Lennox-Gastaut syndrome, clobazam is the only 1, 5-benzodiazepine that is currently approved for clinical use in the United States. In previous clinical trials clobazam has been shown to have a greater efficacy and produce fewer side effects in individuals when it's adverse event profile is compared to the traditional 1,4-benzodiazepines such as diazepam, lorazepam, and clonazepam. As a benzodiazepine, clobazam has been found to have anticonvulsant properties, and structural differences as a 1,5-benzodiazepines that appear to have a broader spectrum of anticonvulsant activity than those found in 1,4-benzodiazepines. In previous reports, clobazam has been seen to be effective in ether terminating or reducing both EPC in particular and partial status epilepticus.

Interventions

  • Drug: Clobazam
    • Comparison of AED use in Epilepsia Partialis Continua
  • Drug: Clonazepam
    • Comparison of AED use in Epilepsia Partialis Continua
  • Drug: Lorazepam
    • Comparison of AED use in Epilepsia Partialis Continua

Arms, Groups and Cohorts

  • Experimental: Clobazam
    • Subjects who are assigned the clobazam treatment group will receive a 10mg loading dose followed by a maintenance dose of 5-25 mg bid starting 12 hrs after the loading dose. If subjects are found to have failed to respond to treatment with clobazam, the physician investigator has the ability to either start another AED or increase the dose of clobazam depending on the clinical situation. Subjects still being treated with clobazam at discharge will be given a 30 day supply of clobazam.
  • Active Comparator: Clonazepam
    • Subjects who are assigned to the clonazepam treatment group will receive a dose of 1-2mg clonazepam dose tid. Following the initial treatment if a physician investigator determines that the subject’s treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
  • Active Comparator: Lorazepam
    • Subjects who are assigned to the lorazepam treatment group will receive a 1-2mg dose of lorazepam qid. Following the initial treatment if a physician investigator determines that the subject’s treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.

Clinical Trial Outcome Measures

Primary Measures

  • Time (measured in minutes) to onset of seizure freedom
    • Time Frame: Within 7 days
  • Reduction of seizure frequency/minute
    • Time Frame: Within 7 days

Secondary Measures

  • Mental status preservation off sedating anticonvulsants as measured by the MoCA© scale
    • Time Frame: Within 37 days
  • Ambulatory function as measured by the Hauser Ambulation Index
    • Time Frame: Within 37 days

Participating in This Clinical Trial

Inclusion Criteria

•≥ to 18 yrs of age •Diagnosis of EPC by a Neurologist Exclusion Criteria:

  • Previous exposure to clobazam prior to presentation – Seizure generalization – Patients who are intubated and on IV sedation such as Versed®, Propofol or Presedex®. – Female subjects who are pregnant and/or breast-feeding – Subject has an unstable and/or serious or psychiatric illness – Subject has an unstable and/or serious medical illness – Subject has any of the following but not limited to conditions: – A life threatening medical condition – Severe sepsis or septic shock – Severe Renal impairment – Severe Hepatic impairment – Sleep apnea – Narrow angle glaucoma – Severe respiratory insufficiency – Myasthenia gravis – Metastatic cancer – Organ failure – Severe progressive nervous system disease – A clinically significant EKG abnormality that would be affected by and/or affect the patient's participation in the trial – Subject has active suicidal ideation at Screening and Baseline visits – Subject has a history of suicidal thoughts or behaviors, which would be indicated by a positive response to questions 4 and/or 5 on the CSSR-S. Exclusionary actions include but are not limited to: – Previous intent to act on suicidal ideation with a specific plan – Previous preparatory acts or behavior – A previous actual attempt, interrupted attempt or aborted suicide attempt – Subject has a history of alcohol and/or substance abuse in the previous 12 months, or the subject is unable to refrain from alcohol and/or substance abuse during the study. – Subject admits to present illicit drug use or has a positive drug screen – Subject is currently enrolled in or has been enrolled in any clinical trial within the past 30 days – Subject has a known allergy to any component of the study medication(s)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The Cooper Health System
  • Collaborator
    • Lundbeck LLC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Melissa Carran, MD, Principal Investigator, Cooper University Health System

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.